Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« A Re-Org at Novartis | Main | A Landmark In Clinical Trial Data Interpretation »

April 16, 2010

Generex: Who Buys This Stuff, Anyway?

Email This Entry

Posted by Derek

I've been meaning to do another post on Generex, the company that says it's developing an oral spray form of insulin as an alternative to the injected forms. This is the outfit that's suing Adam Feuerstein of TheStreet.com over his dismissive comments on their business, and here I stated that after looking the operation over a bit, that I agreed with him. In short, I have doubts about the real-world efficacy of buccal insulin delivery, doubts about the acceptance of it in the diabetes patient (and physician) population, and doubts that spring from Generex's own statements about the drug's development. A handful of patients in Ecuador does not make for a convincing reason to move into Phase III - not to me - and you don't press-release your Phase III results when you've only enrolled 10% of your targeted number of patients. And so on. . .but who am I to question the buccal spray delivery technology, when (as Generex states on their web site) it's also being used to develop an "energy spray" called Ba-Boom? (Be sure to turn up your speakers so you can hear the theme music; it's going to play when you click that link. And yes, that is Generex - look at the bottom of the page).

It's been a very busy week around here, but what I do have time to do is take a look at the recent infusion of capital the company has experienced. An investment group called Seaside 88 has announced their intention to buy a large amount of Generex stock. Among the Generex investors calling for my head (and other parts of my anatomy), opinion seems divided about Seaside 88 and my relationship to them (which, let me state right up front, is completely nonexistent - I'd never heard of the outfit until this stuff came up). Some of the hardy GNBT folks point to this deal as evidence that I'm a fool, because here's this big investment outfit pouring money into this wonderful company and its promising product. Others seem to think that I'm being paid off by said big investment outfit, that I'm a black-hatted stock-basher out to secure Seaside 88 a better deal as it scoops up this wonderful stock on the cheap.

Which exciting story to believe? Not for the first time, I'm reminded that too many people who invest in small "story" stocks have worldviews that resemble the story lines of profession wrestling. I'd call it Manichean, but that's a bit too elevated. No, it's all Good Guys and Bad Guys, and there's no room for someone like me, a person with no money in the game who finds the whole thing bizarre and amusing. The smaller the stock prices involved, by the way, the crazier the investors seem to be.

So, Seaside 88. If you go do an EDGAR search on them, you find that they've done similar stock-purchase deals with a number of small companies (and other deals show up as you Google for press releases). Flywheel energy storage companies, obscure fuel-cell makers - it's quite a collection. My personal favorite is Ensurge, Inc., and if you'd like to know what business they're in, you'll just have to read the language in their 10-K. If you're not snorting in derision by the time you get to the South-American-gold-mining stuff, then you're a born penny-stock investor. You'd have to use threats of bodily harm to make these things a centerpiece of my own investment strategy - but hey, that's why I'm going to finish up eating off-label cat food in a trailer while the Generex shareholders are sailing their yachts through the Greek islands. These things have a way of evening out.

So, who are these Seaside 88 people, anyway? Well, as is often the case, there's a whole little constellation of related companies. There's your Seaside Analytics, your Seaside Capital Management, your Seaside Capital II, and so on. One person who figures prominently in all of them is William Ritger, who's been in the investment business for some years now. Here's a biography of him from one of the companies he's helped to found.

In fact, he's been in the business long enough for this article from the the New York Times to turn up. It refers to a former venture of his, Research Works, which seems to have issued favorable reports on obscure stocks - causing their prices to jump - but without making much of the fact that he was being paid by the companies involved to write those reports. One hopes that he is no longer in the business of promoting small stocks in this manner.

Another name that shows up when you search the Seaside family of investment partnerships is Denis O'Donnell. Looking over the EDGAR filings featuring his name, you find his ongoing relationship with a company called American Bio Medica, which I note has also been listed as one of the house favorites of a micro-cap "pump and dump" junk-fax operation. He's also been involved with Columbia Laboratories - now of New Jersey, but formerly of Hollywood, Florida, where (interestingly enough) they were mentioned in that same New York Times article as the subject of one of those paid-for investment reports back in the 1990s. One hopes that he is keeping better company now.

So, Generex investors, enjoy your stock, and enjoy the company of the others who have seen fit to invest in it. I will not be putting any of my own money into it, and they won't let a person short companies that trade at 60 cents a share. Which is too bad, in a way, because the great majority of such companies go to zero.

Comments (43) + TrackBacks (0) | Category: Business and Markets | Diabetes and Obesity | The Dark Side


COMMENTS

1. Keith Robison on April 16, 2010 8:23 AM writes...

AHA! So that's your twisted little game! You're trying to pump the price back up to $1.00 so you can short it down to zero.

Devious, but the Generex community is on to you now!

Permalink to Comment

2. rjs9787 on April 16, 2010 8:37 AM writes...

I was hoping for something more enlightening from you Derek. I feel like I read a Yahoo message board post. How silly.

Permalink to Comment

3. Anonymous on April 16, 2010 9:01 AM writes...

Cero che ne spari di stupidaggini!

Permalink to Comment

4. Anonymous on April 16, 2010 9:08 AM writes...

I just found this on the web about Derek Lowe ... Yea he's a real success story... From nature.com
Derek Lowe is a research chemist in the pharmaceutical industry. Despite nearly twenty years of trying, he has yet to put anything on the market, so if you're looking for a reason for high drug costs, look no further.

Yeah you should really be bashing other peoples work

Permalink to Comment

5. Anonymous on April 16, 2010 9:19 AM writes...

Have you done any research on generex Oal Lynn . Maybe this means something from the FDA:
Skip to Main Content
Home Search Study Topics Glossary


Study 72 of 122 for search of: expanded access studies AND expanded access trials
Previous Study Return to Search Results Next Study



Full Text View



Tabular View



No Study Results Posted



Related Studies


Treatment Study of Generex Oral-lyn™ in Patients With Diabetes
Expanded access is currently available for this treatment.
Verified by Generex Biotechnology Corp., September 2009
First Received: July 27, 2009 Last Updated: September 28, 2009 History of Changes
Sponsor: Generex Biotechnology Corp.
Information provided by: Generex Biotechnology Corp.
ClinicalTrials.gov Identifier: NCT00948493
Purpose
The purpose of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus that have no satisfactory alternative therapy available for treatment of diabetes, and who are not eligible to participate in the ongoing pivotal clinical trial.

Condition Intervention
Diabetes Mellitus
Drug: Generex Oral-lyn™

Study Type: Expanded Access
Official Title: An Open-Label Treatment Investigational New Drug (IND) for the Use of Generex Oral-lyn™ in Patients With Type 1 or Type 2 Diabetes Mellitus

Resource links provided by NLM:

MedlinePlus related topics: Diabetes
U.S. FDA Resources

Further study details as provided by Generex Biotechnology Corp.:

Intervention Details:
Drug: Generex Oral-lyn™
Generex Oral-lyn™ will be given in a split-dose fashion (half of the dose immediately prior to the meal and half of the dose immediately after the meal)
Detailed Description:
This is an open-label Treatment IND for the use of Generex Oral-lyn™ in patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus that have no satisfactory alternative therapy available for treatment of diabetes, and who are not eligible to participate in the ongoing pivotal clinical trial (Protocol GEN-084-OL). This Treatment IND is open to anyone who meets the inclusion and exclusion criteria. There are no oral or injectable medications contraindicated for this study. Patients may or may not be on long-acting insulin. They will continue their current treatment on entry into the study.
Eligibility

Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Patients with Type 1 or Type 2 diabetes mellitus (according to ADA and/or WHO classification) and have therefore, by current definition of the condition, evidence of risk to organ damage;
There is no satisfactory alternative treatment available;
Willing to give written informed consent prior to admission into the Treatment IND.
Exclusion Criteria:
Have positive pregnancy test, or is a breast feeding woman, or a woman not using an adequate method of contraception;
Have an active oral lesion(s) and/or active disease involving the oral cavity.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00948493

Contacts
Contact: Dennis Gage, M.D. 212-772-7628

Locations
United States, New York
Beth Israel Medical Center, Department of Medicine, 103 East 75th Street
New York, New York, United States, 10021
Contact: Dennis Gage, M.D. 212-772-7628
Principal Investigator: Dennis Gage, M.D.
Sponsors and Collaborators
Generex Biotechnology Corp.
Investigators
Principal Investigator: Dennis Gage, M.D. Beth Israel Medical Center
More Information

No publications provided

Responsible Party: Generex Biotechnology Corp. ( George E. Markus )
Study ID Numbers: GEN-100-OL
Study First Received: July 27, 2009
Last Updated: September 28, 2009
ClinicalTrials.gov Identifier: NCT00948493 History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Generex Biotechnology Corp.:
Treatment IND

Additional relevant MeSH terms:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on April 15, 2010

Back to top of Main Content

Contact Help Desk
Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,
U.S. National Institutes of Health, U.S. Department of Health & Human Services,
USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act

Links to all studies - primarily for crawlers

Permalink to Comment

6. Derek Lowe on April 16, 2010 9:21 AM writes...

RJS, I know you're a fan of the stock. I wish you well with it. But I doubt if you'd consider anything I wrote about it "enlightening" unless it agreed with your view of the company's prospects. And I can't manage to do that: almost nothing about Generex inspires confidence in me.

Besides, there are too many capital letters and correctly spelled words for this to pass for a Yahoo post. Not to mention too few random punctuation marks. . .

Permalink to Comment

7. Sili on April 16, 2010 9:27 AM writes...

Lovely. Do they have any stock in Steorn and Blacklight as well?

I actually have some penny stock, but it's not more than I'm willing to lose. I guess it's like the lottery, but without the charitable aspect.

Permalink to Comment

8. Henning Makholm on April 16, 2010 9:28 AM writes...

"Typical users of BaBOOM!™ are those who want that quick burst of energy without overloading their bodies with the extra calories"

I suppose typical investors are those who want that quick profit without overloading their finances with the extra dollars.

Permalink to Comment

9. Anonymous on April 16, 2010 9:30 AM writes...

On a more sciency note there is an ASAP out in Drug Discovery Today that appears to offer a nice look at exactly the intra nasal absorption of insulin. Its published by a group out of Shenyang Pharmaceutical Univeristy in China.
Truth be told I haven't completely read through it but it is sensibly cautious about the current prospects of this kind of drug delivery. Paraphrased, some sections read like:
There are ways of getting it absorbed through the mucus membranes effectively, but these often irritate the hell out of your nose, so new avenues are still being sought.
Just thought I'd throw it out there

Permalink to Comment

10. tc2000chartreader on April 16, 2010 9:34 AM writes...

Derek,
All you are doing is a review of Seaside 88. Who cares about that. I personally don't like the deal, but that does not negate all the products Generex has to offer, or are working on.

Permalink to Comment

11. Hap on April 16, 2010 9:51 AM writes...

tc...: No, it doesn't...but the sketchy trials of insulin in nations most people might not be able to find on a map, the inability to actually sign up enough people in those havens to do real clinical trials (of even the ones they intended to do), the lack of a business model for oral insulin (particularly in light of the failures of people who actually worked hard on related concepts, got actual clinical trial data, and lost their shirts anyway) that doesn't require massive amounts of mind-altering drugs to believe, and the (pretty good) potential for their management to be looking at some nice penalties from the folks at the SEC - those seem like pretty good reasons to discount the substance of Generex's product line. Discussing Generex's product line as an argument for investing in them is the intellectual equivalent of bringing a spork to a gunfight. The sketchiness of their investors...well, that's the rotten algae icing on top of the congealed sewage cake that is their stock position.

Oh, and as a side note, I don't see Merck whipping its "HotLine" brand of energy inhalers "for when you need that extra push". Something about legitimate pharmaceutical companies not wanting to play in the land of liars and shills. (Of course, that analogy only goes so far - see the cozy relationship between banks and payday lenders in my home state.)

Permalink to Comment

12. rjs9786 on April 16, 2010 9:52 AM writes...

Yes Derek, but your comment that Generex filed a lawsuit over dismissive comments is false. The comments made by Feuerstein were totally erroneous. Some are as valid as your claim that there have only been studies in a handful of patients in Ecuador, which is only true if ignorance blinds one from recognizing the earlier studies in England, Italy, Israel, Canada and the US. But a detailed and thoughtful analysis about Oral-lyn, never mind Antigen Express, took a backseat to selective disclosure about an investment firm.

Permalink to Comment

13. rjs9786 on April 16, 2010 9:53 AM writes...

Yes Derek, but your comment that Generex filed a lawsuit over dismissive comments is false. The comments made by Feuerstein were totally erroneous. Some are as valid as your claim that there have only been studies in a handful of patients in Ecuador, which is only true if ignorance blinds one from recognizing the earlier studies in England, Italy, Israel, Canada and the US. But a detailed and thoughtful analysis about Oral-lyn, never mind Antigen Express, took a backseat to selective disclosure about an investment firm.

Permalink to Comment

14. rjs9787 on April 16, 2010 10:02 AM writes...

Sorry, fat thumb on small phone! :) Too silly, be well.

Permalink to Comment

15. Hap on April 16, 2010 10:07 AM writes...

Still haven't explained their silence over India, though.

Permalink to Comment

16. weirdo on April 16, 2010 10:09 AM writes...

Hey, this is fun, kind of like poking a hornet's nest!

Anon#5 -- what is your point? We all know Generex is running a clinical trial -- they put out a press release to that effect. What do you expect out of that trial? It doesn't even appear to be a trial that can lead to approval (note that it's open label, with no comparator).

rjs -- You just lied, can Derek sue you? AF's comments were indeed "dismissive". You go on to state they are "totally erroneous", but that does not mean they were not also dismissive. Maybe you should go find a dictionary and look up the meaning of the word "dismissive". So, you have publically accused Derek of lying in written form; that, sir is called libel, and Derek should sue your ass back to the stone age. AHAHAHAHAHAHAH! Now HE gets the yacht crusing the Greek Isles! AHAHAHAHAHAHAHA!!

Permalink to Comment

17. Vader on April 16, 2010 10:20 AM writes...

Hang in there, Derek. Anything that brings out the tools (rjs9787 sounds like a robot name) is worth continuing to talk frankly about.

Permalink to Comment

18. joel on April 16, 2010 11:12 AM writes...

No way! I actually tried that "Ba-boom" spray after a few, uh, adult beverages and an ill-advised trip to the corner store. It made my mouth taste like rat's butt and didn't make me any more alert.

Yes, I am somewhat of an expert on gimmicky "energy" goods. I blame grad school.

Permalink to Comment

19. Dan on April 16, 2010 11:59 AM writes...

The addition of an "All Natural Male Enhancement Supplement" is all Generex needs to fully round out the product portfolio.

Legal documents are being drawn up by Pfizer, Red Bull, and Enzyte for the rights to purchase this promising pipeline.


Permalink to Comment

20. AmyT of www.diabetesmine.com on April 16, 2010 12:17 PM writes...

For the record, I think the oral insulin spray product is a bad idea (ie not going to work).

For clarification, see my buddy Scott's comments on the matter:
http://sstrumello.blogspot.com/2009/11/business-of-diabetes-generex-vs.html

Permalink to Comment

21. Harry on April 16, 2010 12:46 PM writes...

Hmmm not exactly like poking a hornet's nest, since hornets have a sting. More like disturbing the fruit flies nesting on a rotten banana. Lots of tiny annoying critters flying around, but nothing much accomplished.

Permalink to Comment

22. bbooooooya on April 16, 2010 12:55 PM writes...

These purchase agreements are great....for the funds you have a guarantee of getting the shares at a discount.

For a stock like gnbt, with avergae volume of almost 3 million/day this is as close to pure play arbitrage as you can get. For me, if I could get those terms I'd be shorting this pig (even at 4 bits) all day, safe in the knowledge my downside is limited. those Seaside guys are smart. GNBT retail shareholders are going to get hosed, but it's really not about them....

Permalink to Comment

23. Christian Hesketh on April 16, 2010 3:06 PM writes...

"Which exciting story to believe? Not for the first time, I'm reminded that too many people who invest in small "story" stocks have worldviews that resemble the story lines of profession wrestling. I'd call it Manichean, but that's a bit too elevated. No, it's all Good Guys and Bad Guys, and there's no room for someone like me, a person with no money in the game who finds the whole thing bizarre and amusing. The smaller the stock prices involved, by the way, the crazier the investors seem to be."

This is the funniest and most true comment I think I've ever read on a blog. You've made my day Derek, thanks!

Permalink to Comment

24. Pharma Conduct Guy on April 16, 2010 4:14 PM writes...

You know, I was all excited about investing in Generex until reading Derek's critique. After that, I decided I'd be better off take the $500k I was considering putting into Generex and buying some magic beans instead. But now, after reading all of the helpful followup here, I realize that Derek was simply overlooking a valuable gem in the rough. Go Generex, Go!

Permalink to Comment

25. Frank on April 16, 2010 7:10 PM writes...

It never ceases to amaze me just how much controversy this little company stirs.
Wherever a forum pops up to discuss it, the same characters appear to continue the battles they wage elsewhere. With all due respect, Adam's comments were phrased in manner that is legally liable. Perhaps the unfolding of this legal battle will cast a light on the so-called questionable issues. Its nice to learn that you frequent the YMB enough to notice the poor spelling and random punctuation.

Permalink to Comment

26. Eddy on April 16, 2010 10:16 PM writes...

There is a small group of vocal investors led by RJS that slam anyone that says anything negative about GNBT. They've been in this stock for years and have lost a lot of money. They are angry and frustrated and as such they lash out at others when they only have themselves to blame. They are generally a pretty clueless bunch. You don't have to be a genius to uncover all the glaring red flags when doing due diligence on GNBT. Its like buying a used car. If you walk up to the car and its blowing blue smoke, the tire wear is uneven, there is some evidence of re-paint in the wheel wells, and there is a slight musty odor inside the car, you don't need to waste your time on this clunker (GNBT) by doing an "enlightening" 10 page report. There are 100 other better cars (stocks) on the lot. Even if GNBT might squeak out some sales at some point, you've just missed the opportunity to get in early in the next google or apple.

Permalink to Comment

27. See Alice on April 17, 2010 4:36 PM writes...

It's hilarious how quickly you get a rise out of the GNBT investors. The fun is almost a guilty pleasure, like making a mess in a room full of OCD people or giving a jeopardy-esque scavenger hunt to mentally challenged individuals. I think the poster who mentioned bringing a spork to a gunfight captured that same feeling.

The information is out there, it is as dubious as you say, and yet some are too invested to see the obvious. Even better, because of the pump and dump nature of the small caps (or at least as these people apparently invest in them), they have to vigorously trumpet their shortcomings and try to badger or convince others of idiocy to minimize their losses.

Maybe you should tag this under "How Not To Do It: Stock Selection."

Permalink to Comment

28. Resveratrol Baby Daddy on April 17, 2010 6:12 PM writes...

My company also has a diabetes product in its transformational pipeline: 1) lyophilized insulin which can be snorted from tables, strippers, and other flat, and relatively flat, surfaces. (Our scientists daily demonstrate their devotion to improving the lives of patients by identifying more of these surfaces.)

Permalink to Comment

29. tom on April 17, 2010 6:46 PM writes...

It's funny to read the opinions of the non-pinioned; cliches, innuendos, and blog followers. Probably none of these posters are against GNBT, but just need to be heard somewhere. They know nothing of the years of research and clinical trials of the buccal insulin spray, or, that no other company has come up with a way to penetrate the buccal areas with a large molecule drug. This drug is human insulin, not synthetic or otherwise.

I want the readers here to tell this board who, other than Generex Biotechnology has accomplished this feat. No matter how many "units" in each application or otherwise. C'mon, lets hear from all you non-believers, and please, don't minimize this accomplishment by saying "penny stock" or, "scammer stock", without any real due diligence in your proof or substance of why GNBT can be wholly identified as such.

The FDA, note, the Food and Drug Administration has already given a thumbs up on the safety and efficacy of Oralyn by allowing Generex to set up clinics across the nation to allow patients to use the spray that could nor reasonably utilize other insulin avenues to treat their diabetes.

This is an information exchange board, not an "protest whoever Adam hates" stock board.

Go ahead.

Permalink to Comment

30. Frodo on April 17, 2010 8:05 PM writes...

i freekwunt th yahoo messge boreds al lots :) :) dont give bads names tu them LOL :} many smart peoples thar f u take the time . evrything i know comes from internets

u guyz talk too much

When Derek starts sounding like a Yahoo Message Board, we will know the Apocalypse is close at hand. By the way, Derek, you left out a bunch of emoticons. You can't be a valid message boarder without those, and at least a couple of dozen LOL's.

Permalink to Comment

31. bbooooooya on April 17, 2010 8:26 PM writes...

"The FDA, note, the Food and Drug Administration has already given a thumbs up on the safety and efficacy of Oralyn by allowing Generex to set up clinics across the nation to allow patients to use the spray that could nor reasonably utilize other insulin avenues to treat their diabetes."

Hmmmm, no, your statement is untrue. The FDA has agreed that the treatment warrants further study. It will not have been proven safe and effective until an NDA is approved. Sadly, it is idiot pumpers like you who give biotech stocks a bad name. Please stop lying.

Permalink to Comment

32. rjs9787 on April 17, 2010 9:37 PM writes...

*Derek's comments:

"Generex, the company that says it's developing an oral spray form of insulin" (The compant IS developing etc etc.)

"suing Adam Feuerstein of TheStreet.com over his dismissive comments" (Generex is suing Adam Feuerstein over his false and malicious etc etc.)

"A handful of patients in Ecuador does not make for a convincing reason to move into Phase III - not to me" (Total lack of familiarity with earlier trials in US, Canada, Italy, England and Israel.)

*Derek wants to be portrayed as a victim of unfair criticism:

"Among the Generex investors calling for my head (and other parts of my anatomy)"

"Some of the hardy GNBT folks point to this deal as evidence that I'm a fool"

"Others seem to think that I'm being paid off by said big investment outfit, that I'm a black-hatted stock-basher"

*When it is he who paints all GNBT investors in a nasty light and who wrestles in mud:

"Generex: Who Buys This Stuff, Anyway?"

"too many people who invest in small "story" stocks have worldviews that resemble the story lines of profession wrestling."

"The smaller the stock prices involved, by the way, the crazier the investors seem to be."

"So, Generex investors, enjoy your stock, and enjoy the company of the others who have seen fit to invest in it."

*From many of the immauture comments here we can see the company Derek keeps, as well as Feuerstein's 'shout outs' to him on Tweeter.

*Did he mention that Generex also has many intelligent investors? What about this gentleman:

"Dr. Devine reports receiving consulting fees from Medacorp, MDLinx, and Guidpoint Global, equity ownership in Evergreen solar, Openwave, Unifi, Novavax, Genaera Pharm, and Generex Biotech."
http://americanheart.mediaroom.com/index.php?s=43&item=883

*That wouldn't fit the narcissistic routine of pitting Derek against fools. Derek states "there's no room for someone like me, a person with no money in the game who finds the whole thing bizarre and amusing."

His jumping into the Feuerstein fray was bizarre and amusing. In his first article, he states that "why treat a handful of people in Ecuador and let your stock value sit at 60 cents a share, if you have the chance to raise the serious money needed to get a real diabetes therapy through some convincing Phase III trials instead? That's not how this business tends to work."

Well, that is exactly what Generex has been doing, and the Ecuador comment is false. And the latest investment commitment led to his selective reflections of an investment firms business decisions which omit the ones that have led to nice gains.

*Motivation to inform, or incite?

Derek wrote here last week: "That increases my interest in the company even more, now that I see what high-caliber fans it has. Look for an article on Generex here next week. From what I've been able to find already, I should have something the company's cheering section will enjoy."

Derek's blog is titled- "In the Pipeline"- yet he goes as far as researching Baboom? I'll help him delve a bit deeper by showing the Ph 1 results being presented as we speak for Generex's AE37 vaccine with prostate cancer patients:

"Local and systemic toxicities beyond grade 2 were not observed. 23 patients had (+) delayed type hypersensitivity (DTH) responses following immunization and 15-23 had specific responses in ELISPOT and/or intracellular staining, respectively Median progression-free survival for DTH responders was 18 months compared to 1 month for DTH non-responders. 15 patients who received no other treatment during the vaccination period had stable (6 pat) or decreased (9 pat) PSA post vaccination."

And that comes on the heels of the recent successful Ph 2 data for AE37 with breast cancer patients where interim results show there were no (0.0%) recurrences in the AE37 group of patients, 0/49, compared to 7.0%, 5/71, in the control group.
http://www.posters2view.com/sabcs09/viewp.php?nu=3183

That is true Generex "In the Pipeline" commentary.

Permalink to Comment

33. Anonymous on April 18, 2010 8:51 PM writes...

Generex is owned by George W. Bush.

Permalink to Comment

34. J-bone on April 19, 2010 7:13 AM writes...

My company also has a diabetes product in its transformational pipeline: 1) lyophilized insulin which can be snorted from tables, strippers, and other flat, and relatively flat, surfaces.

Is your company hiring? I'd like to volunteer to test that 2nd surface.

Permalink to Comment

35. Anonymous on April 19, 2010 9:40 AM writes...

Wasn't "Generex" the name of the company in "Jurassic Park" that was cloning dinosaurs?

Maybe it was "InGen". Close enough.

Permalink to Comment

36. Hap on April 19, 2010 10:03 AM writes...

Still no comment on India. Wonder why.

Permalink to Comment

37. weirdo on April 19, 2010 10:06 AM writes...

Wow, the hits just keep on coming. rjs's (re)-posts a lot of stuff trying to make a point. What it is, is not clear. Congratulations, sire, you can cut and paste.

Now, "tom" posts a flat-out lie: "the Food and Drug Administration has already given a thumbs up on the safety and efficacy of Oralyn by allowing Generex "

FDA hasn't commented on the safety and efficacy. This is a pretty typical trial Generex is running. But it clearly, obviously, 100% does NOT mean the FDA thinks this stuff works and/or is safe. (Yet!).

Keep piling on the s**t boys, this ain't a message board full of Yahooligans like you're used to.

Permalink to Comment

38. Petros on June 22, 2010 9:17 AM writes...

The latest ADA meeting is about to occur.

Rather than present in the meeting Generex is taking a trade stand to show its data!

http://investor.generex.com/releasedetail.cfm?ReleaseID=481651

Permalink to Comment

39. michael on August 9, 2010 1:55 PM writes...

I for one am intrigued by Generex's product as I am a 3d generation diabetic (as far as is known). Although I am a type 2 patient the future at some point will probably include insulin injections at some point. I realize this might all be a pipe dream but it was a small enough risk to buy some GNBT when it was 11 cents. If it is a miss I am out small change and if it succeeds I have an alternative. The market is a risk anytime, however the gambit of moronity over a penny stock amazes me. For the record this is the only penny stock I own with everything else being blue chip.

Permalink to Comment

40. molly on August 13, 2010 5:19 PM writes...

I just found this site today and posted a question on the author's more recent post on Oral-Lyn. Michael, your comment hit home for me. I don't care one whit about the investment side of Generex. People who are not faced with injecting themselves should not cavalierly dismiss the appeal of a non-needle alternative. I am actively involved in pursuing Oral-Lyn for myself and my highly-qualified physician (a respected endocrinologist and diabetes specialist) has said it is safe. I am hopeful.

Permalink to Comment

41. Agustin Woll on May 22, 2012 2:32 PM writes...

Catholic News: Jesus Christ reincarnation Tom Truong has decided to grant the human race free online college education to billions of people world wide. Go tell everyone.

Permalink to Comment

42. Morgan on November 1, 2012 10:23 AM writes...

Thanks for sharing this information with us. It seems like a big medical advance if they could get it to work. It could improve the quality of lives for many people. This was a very interesting article to read.
hvac service modesto ca

Permalink to Comment

43. Morgan on November 1, 2012 10:24 AM writes...

Thanks for sharing this information with us. It seems like a big medical advance if they could get it to work. It could improve the quality of lives for many people. This was a very interesting article to read.
hvac service modesto ca

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Scripps Update
What If Drug Patents Were Written Like Software Patents?
Stem Cells: The Center of "Right to Try"
Speaking of Polyphenols. . .
Dark Biology And Small Molecules
How Polyphenols Work, Perhaps?
More On Automated Medicinal Chemistry
Scripps Merging With USC?